Viable biobanking of primary head and neck squamous cell carcinoma§

Authors

  • Jose M. Godoy MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Andrew Sewell MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Benjamin Johnston MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Brandee T. Brown BS,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Xinyuan Lu BS,

    1. Department of Cancer BiologyVanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Robert J. Sinard MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Sarah Rohde MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Kyle Mannion MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • James L. Netterville MD,

    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    2. and Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    Search for more papers by this author
  • Wendell G. Yarbrough MD

    Corresponding author
    1. Department of Otolaryngology,Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    2. Department of Cancer BiologyVanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    3. and Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee, U.S.A
    • Department of Otolaryngology, 7209 Medical Center East, South Tower, 1215 21st Avenue South, Nashville, TN 37232
    Search for more papers by this author

  • Presented at the Triological Society Combined Sections Meeting, San Diego, California, U.S.A., April 18–22, 2012.

  • This study was supported by an endowment to the Barry Baker Laboratory for Head and Neck Oncology, Vanderbilt Ingram Cancer Center, Vanderbilt Bill Wilkerson Center, Vanderbilt Department of Otolaryngology, and Vanderbilt Clinical and Translational Science Awards grant UL1 RR024975-01 from National Center for Research Resources/National Institutes of Health.

  • §

    The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Abstract

Objectives/Hypothesis:

To determine the feasibility of viable storage of head and neck squamous cell carcinoma (HNSCC) for regrowth of cells in culture.

Study Design:

Laboratory-based translational study.

Methods:

Methods for intermediate-term frozen storage of viable HNSCC were explored using small pieces of primary tumor and dissociated HNSCC cells after short-term culture. Viable cells after freezing were confirmed by adherence to tissue culture plates, cell morphology, and increased cell or colony density. Two cultures were immunostained for cytokeratin to confirm epithelial origin of viable cultured cells after freezing.

Results:

Six primary HNSCCs (two oral cavity, three larynx, one oropharynx) and two HNSCCs that had been passaged through a xenograft (two oral cavity) were dissociated to single cells and grown in short-term cell culture for 0 to 12 passages. After short-term culture, cells were frozen for up to 8 months, thawed, and replated. Frozen cells derived from all tumors (six primary and two xenografts) were successfully replated with cultures lasting >7 days with seven of eight tumors presenting increased colony or cell density over 1 week of growth after freezing. In total, 15 of 15 tested samples derived from six primary and two xenografted HNSCCs were viable after freezing.

Conclusions:

In the current study, we show that biopreservation of primary or xenografted HNSCC using short-term cell culture is feasible. Initial short-term cell culture was required for successful storage and viability of frozen cells. These proof-of-principle studies, if more widely implemented, could improve preclinical testing of new therapies for HNSCC. Laryngoscope, 2013

Ancillary